Mutations in a broad spectrum of tumors, such as breast, bladder, colon, gastric cancer and glioblastomas [22, 23] and at much lower frequency in NSCLC cause aberrant activation of phosphatidylinositol 3-kinase (PI3K)/AKT signaling. The gene discussed is AKT1; the disease is non-small cell lung carcinoma.